PTPhuong Bich Tran

Phuong Bich Tran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Phuong Bich Tran has a total of 147 co-authors. Here are the top co-authors by number of shared publications:

  • Finaba Berete

    Department of Epidemiology and Public Health, Sciensano , Brussels

    3 shared publications
  • Johan Van der Heyden

    Department of Epidemiology and Public Health, Sciensano , Brussels

    3 shared publications
  • Josefien van Olmen

    Department of Family Medicine and Population Health, University of Antwerp , Antwerp

    3 shared publications
  • Joseph Kazibwe

    Department of Clinical Sciences, Lund University, Malmö, Sweden

    3 shared publications
  • Anastasios Bastounis

    Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK

    2 shared publications
  • Andrew Booth

    Sheffield Centre for Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK

    2 shared publications

Latest Publications

  • Open Access

    Ecosystem Restoration and Human Health: A Scoping Review (2015-2025)

    by James Prendergast, Jennifer S. Lord, Phuong Bich Tran, Sinead O'DOherty, Melissa Reid, Sophie Foster, Matthew Sheel, Ewan M. Tomeny

    Background: Ecosystem restoration, used here as an umbrella term (e.g., rewilding, reforestation, wetland rehabilitation, river re-naturalisation, species reintroduction, soil regeneration), is gaining momentum as a potential nature-based solution with public health co-benefits. However, evidence that specifically links exposure to restored/rewilded ecosystems (beyond generic greenspace) to measured health outcomes remains fragmented. Objective: To map and characterise evidence on associations between exposure to recently restored or rewilded ecosystems and human health and well-being outcomes. Methods: A scoping review (2015–2025) was conducted following JBI guidance and reported per PRISMA-ScR. Databases searched: PubMed, Scopus, GreenFILE, Environment Complete, and Discovery (last search 10 March 2025). Title/abstract screening was undertaken independently by two reviewers in Rayyan with multidisciplinary consensus resolution; a third reviewer adjudicated persistent uncertainties. Data were charted using a pre-piloted extraction framework and were synthesised thematically; no critical appraisal was undertaken, consistent with scoping methodology. Results: Included studies (N = 19) spanned multiple continents and restoration modalities (e.g., forest landscape restoration, natural regeneration, wetland/coastal rehabilitation, species reintroductions). Mental well-being and broader quality-of-life outcomes predominated; physical health outcomes were less common. The overall direction of effect was largely beneficial, with isolated negative perceptions in certain concepts. Framing varied: a subset explicitly examined restoration (more likely to measure biodiversity/quality), while others treated exposure implicitly as access to "natural" areas, often assuming ecological quality. Conclusions: Restored and rewilded ecosystems appear promising interventions for human health and wellbeing. Furthermore, an integrated approach to human and environmental health has been proposed to aid future research, which should integrate biodiversity/quality metrics with health outcomes, adopt equity-centred designs, and employ longer-term approaches to inform policy and practice.

  • Open Access

    A model-based evaluation of the cost-effectiveness of paediatric and elderly vaccination against pneumococcal infection in England

    by Matt J. Keeling, Omar El Deeb, Phuong Bich Tran, Stavros Petrou, Edward M. Hill

    Infection with pnuemococcus bacteria is generally mild but can be more severe in the young and elderly, causing invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP). Although paediatric pneumococcal conjugate vaccine (PCV) programmes and elderly pneumococcal polysaccharide vaccine (PPV) programmes have reduced cases, we estimate that pneumococcal infection still leads to direct health care costs of around £68M and approximately 16 thousand QALY losses in England per year. The public health situation is complicated by the large number of interacting serotypes, such that while serotype-specific vaccines reduced the target serotypes others arose to replace them. Here we develop a novel (relatively) low-dimensional model to capture the interaction of 26 common pneumococcal serotypes. The model is matched to English IPD data from 2000-2023 and to five carriage studies (conducted in 2001/02, 2008, 2012, 2015 and 2018). When combined with a health economic approach, this model allows us to calculate the willingness to pay for paediatric vaccination with PCV7 (introduced in England in 2006), PCV13 (introduced in England in 2010) and the future vaccination of both the young and elderly with PCV20, which offers protection against 20 serotypes. Due to rapid serotype replacement, we find that the introduction of PCV7 vaccination in 2006 was not cost effective - a result that could not have been anticipated at the time, but is supported by simple statistical fits to the IPD data. In contrast, switching to PCV13 in 2010 and switching to PCV20 in 2026 are both associated with a high willingness to pay for a single dose. Given pneumococcal disease has shifted over time to become predominantly in the older adult population, we find that switching from PPV23 to PCV20 vaccination in those aged 65 and introducing an additional PCV20 vaccine at age 75 are both cost effective for a sufficiently low vaccine price. The inference that underpins our model is unfortunately limited by the available data and the high-dimensional nature of multiple interacting serotypes. Future sampling of carriage from older adults would greatly improve our confidence, as would national estimates of CAP.

  • Open Access

    Development of a PRISMA extension for systematic reviews of health economic evaluations (PRISMA-EconEval): a project protocol

    by Phuong Bich Tran, Joseph Kwon, Andrew Booth, Anastasios Bastounis, Ewan M. Tomeny, Sophie Staniszewska, Richard Grant, Kednapa Thavorn, Dalia Dawoud, Rafael Pinedo-Villanueva, et al.

    Background: Systematic reviews of health economic evaluations are key for evidence-based decisions but lack standardised reporting. This project aims to develop a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) extension for systematic reviews of health economic evaluations (PRISMA-EconEval). Methods: Project stages include the following: (1) scoping review, (2) Delphi surveys, (3) consensus meeting, (4) piloting, and (5) finalisation and dissemination. The project is overseen by the international multidisciplinary PRISMA-EconEval Management Group (PMG), Advisory Group, and Patient and Public Involvement Group. The scoping review aims to identify candidate reporting items, with the protocol published elsewhere. The global applicability of these items to systematic reviews of health economic evaluations will be evaluated using sample papers from the scoping review, supplemented by nominations from the health economics community or other sources, where necessary. A multi-round online Delphi survey will be conducted to achieve consensus on items for inclusion. A purposive sample of panellists (approximately 200) will be selected, ensuring representation of the following: health economists, systematic reviewers, information specialists, guideline developers, journal editors, healthcare decision-makers, research funders, and public representatives. Across two to three rounds, panellists will use a 1–9 scale to rate each candidate item’s ability to represent the minimum required for reporting, be relevant to all systematic reviews of health economic evaluations, facilitate complete and transparent reporting, and support the quality assessment of both the review and included studies. An online consensus meeting (approximately 30 participants) will refine the wording of items and resolve any disagreements by vote. Health economists independent of the project will apply the draft guidelines to a sample of published studies and identify practical challenges. The PMG will meet to finalise the wording and presentation of the reporting items, ensure consistency with PRISMA 2020, and produce an explanation and elaboration document. Dissemination channels will include peer-reviewed health economics journals, conferences, and the EQUATOR network. Discussion: PRISMA-EconEval aims to improve clarity, consistency, transparency, quality, and overall value of systematic reviews of health economic evaluations. This will benefit researchers, peer reviewers, editors, decision-makers, and ultimately patients and the public through supporting decisions on healthcare resource allocation.


  • Open Access

    Multimorbidity and the indirect cost of productivity loss from health-related work absenteeism in Belgium

    by Phuong Bich Tran, Finaba Berete, Bart De Clercq, Johan Van der Heyden, Josefien van Olmen, Lander Willem

    This cross-sectional observational study aims to estimate the number of days absent from work due to health-related problems among employed individuals with multimorbidity and to quantify the lost productivity value from these absences. Data were obtained from the Belgian Health Interview Survey 2018, comprising employed individuals aged 15-64 (N = 4096). We examined 12 chronic conditions and 57 dyads. The Human Capital Approach was used by multiplying the reported number of days absent by the average wage per person per day, utilizing stratified gross wages from the Belgian Statistical Office. Approximately one-third of the study population reported multimorbidity. For individuals with zero to four+ chronic conditions, mean days of absence were 5.5 (95% CI: 2.3-8.8), 6.8 (95% CI: 2.9-10.7), 14.8 (95% CI: 10-19.6), 24 (95% CI: 17.8-30.2), and 36.2 (95% CI: 30.4-42), respectively. Depression (€3089; 95% CI: 2129-4049), diabetes (€2315; 95% CI: 962-3668), arthropathies (€1972; 95% CI: 1101-2844), and cancer (€1848; 95% CI: 598-3099), as standalone conditions, were associated with the greatest productivity losses. The effects were amplified up to seven times with the co-occurrence of multiple chronic conditions. We estimated 34.2 million days absent or €7.5 billion in lost productivity due to health-related work absenteeism among working-age employed individuals with multimorbidity in 2018. At the population level, the coexistence of two musculoskeletal disorders was linked to the highest aggregated productivity loss. At the individual level, the coexistence of a mental health condition and a somatic condition was associated with the highest average productivity loss per capita. The indirect cost due to health-related absence from work for individuals with multimorbidity in Belgium is high, and in many cases, exceeds the direct cost of treatment.


  • Global paid and unpaid productivity losses due to cancer-related mortality

    by Yek-Ching Kong, Jean Niyigaba, Phuong Bich Tran, Jerome Vignat, Freddie Bray, Cindy L Gauvreau, Paul Hanly, Alison Pearce, Marianna de Camargo Cancela, Marta Ortega-Ortega, et al.

    Background: Cancer is among the most important causes of premature deaths globally. We estimated the value of paid and unpaid productivity losses due to premature mortality in 2022 from all cancers worldwide. Methods: Years of productive life lost were derived from cancer mortality data for 36 cancer types among people of working age (15-64 years) in 185 countries for the year 2022. Paid productivity losses were estimated using the human capital approach, while unpaid activities were valued using the opportunity cost approach. Lost productivity was estimated using wages, workforce statistics, and time spent on unpaid activities from various sources. All analyses were performed by sex and age group for each country. Results: In 2022, productivity losses from premature cancer mortality were valued at an estimated US$566 billion, equivalent to 0.6% of the global gross domestic product. Of the total value, 53.9% (US$305 billion) was attributable to paid productivity losses, and 46.1% (US$260 billion) to unpaid productivity losses. Paid productivity losses were generally higher among men, while unpaid productivity losses were greater among women, with variations seen across world regions. The total value of lost productivity was greatest for lung cancer, followed by breast and liver cancers. Per cancer death, testicular cancer, melanoma of the skin, and brain and nervous system cancer generated the highest value of productivity losses. Conclusion: The substantial value of productivity losses from premature cancer mortality highlights its marked societal burden. Continuous investments in global cancer control efforts, including in less common cancers, will yield substantial returns-on-investment to national economies, especially in transitioning countries.


  • Open Access

    Methodological literature on the reporting of systematic reviews of health economic evaluations: a scoping review protocol

    by Phuong Bich Tran, Joseph Kwon, Anastasios Bastounis, Stavros Petrou, Andrew Booth, PRISMA-EconEval Management Group

    Systematic reviews of health economic evaluations play a crucial role in informing evidence-based healthcare decisions, yet they lack standardized reporting guidelines. A project has been initiated that aims to extend the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for systematic reviews of health economic evaluations (PRISMA-EconEval). This scoping review forms a foundation for the PRISMA-EconEval project, aiming to identify, map, and extract candidate reporting items from the methodological literature. The scoping review will follow the PRISMA Extension for Scoping Reviews (PRISMA-ScR) Checklist and involve comprehensive searches in databases such as PubMed MEDLINE, Embase, and Web of Science, covering the period from 2015 to 2024. Supplementary searching, reference checking and citation searching will target grey literature, overlooked studies and evidence prior to 2015. Inclusion criteria will focus on methodological papers that provide frameworks or recommendations for reporting systematic reviews of health economic evaluations and enhanced case studies that critically discuss methods and reporting structures. The extracted data will be coded and analyzed to produce an initial list of candidate reporting items, structured according to conventional sections of a systematic review (e.g., title, abstract, methods, results). This initial list will be used in the subsequent stages of the project and disseminated through a peer-reviewed publication and presentations at international conferences. The outcome of this scoping review will significantly contribute to the development of a comprehensive PRISMA-EconEval reporting guideline, aimed at enhancing the transparency, consistency, and quality of systematic reviews of health economic evaluations, and provide an essential tool for authors, editors, peer-reviewers, and stakeholders.


  • Open Access

    Core outcome sets for trials of interventions to prevent and to treat multimorbidity in adults in low and middle-income countries: the COSMOS study

    by Aishwarya Lakshmi Vidyasagaran, Rubab Ayesha, Jan R Boehnke, Jamie Kirkham, Louise Rose, John R Hurst, Juan Jaime Miranda, Rusham Zahra Rana, Rajesh Vedanthan, Mehreen Riaz Faisal, et al.

    Introduction The burden of multimorbidity is recognised increasingly in low- and middle-income countries (LMICs), creating a strong emphasis on the need for effective evidence-based interventions. Core outcome sets (COS) appropriate for the study of multimorbidity in LMICs do not presently exist. These are required to standardise reporting and contribute to a consistent and cohesive evidence-base to inform policy and practice. We describe the development of two COS for intervention trials aimed at preventing and treating multimorbidity in adults in LMICs. Methods To generate a comprehensive list of relevant prevention and treatment outcomes, we conducted a systematic review and qualitative interviews with people with multimorbidity and their caregivers living in LMICs. We then used a modified two-round Delphi process to identify outcomes most important to four stakeholder groups (people with multimorbidity/caregivers, multimorbidity researchers, healthcare professionals and policymakers) with representation from 33 countries. Consensus meetings were used to reach agreement on the two final COS. Registration: https://www.comet-initiative.org/Studies/Details/1580. Results The systematic review and qualitative interviews identified 24 outcomes for prevention and 49 for treatment of multimorbidity. An additional 12 prevention and 6 treatment outcomes were added from Delphi round 1. Delphi round 2 surveys were completed by 95 of 132 round 1 participants (72.0%) for prevention and 95 of 133 (71.4%) participants for treatment outcomes. Consensus meetings agreed four outcomes for the prevention COS: (1) adverse events, (2) development of new comorbidity, (3) health risk behaviour and (4) quality of life; and four for the treatment COS: (1) adherence to treatment, (2) adverse events, (3) out-of-pocket expenditure and (4) quality of life. Conclusion Following established guidelines, we developed two COS for trials of interventions for multimorbidity prevention and treatment, specific to adults in LMIC contexts. We recommend their inclusion in future trials to meaningfully advance the field of multimorbidity research in LMICs. PROSPERO registration number CRD42020197293.


  • Open Access

    Multimorbidity healthcare expenditure in Belgium: a 4-year analysis (COMORB study)

    by Phuong Bich Tran, Georgios F. Nikolaidis, Emmanuel Abatih, Philippe Bos, Finaba Berete, Vanessa Gorasso, Johan Van der Heyden, Joseph Kazibwe, Ewan Morgan Tomeny, Guido Van Hal, et al.

    Background: The complex management of health needs in multimorbid patients, alongside limited cost data, presents challenges in developing cost-effective patient-care pathways. We estimated the costs of managing 171 dyads and 969 triads in Belgium, taking into account the influence of morbidity interactions on costs. Methods: We followed a retrospective longitudinal study design, using the linked Belgian Health Interview Survey 2018 and the administrative claim database 2017–2020 hosted by the Intermutualistic Agency. We included people aged 15 and older, who had complete profiles (N = 9753). Applying a system costing perspective, the average annual direct cost per person per dyad/triad was presented in 2022 Euro and comprised mainly direct medical costs. We developed mixed models to analyse the impact of single chronic conditions, dyads and triads on healthcare costs, considering two-/three-way interactions within dyads/triads, key cost determinants and clustering at the household level. Results: People with multimorbidity constituted nearly half of the study population and their total healthcare cost constituted around three quarters of the healthcare cost of the study population. The most common dyad, arthropathies + dorsopathies, with a 14% prevalence rate, accounted for 11% of the total national health expenditure. The most frequent triad, arthropathies + dorsopathies + hypertension, with a 5% prevalence rate, contributed 5%. The average annual direct costs per person with dyad and triad were €3515 (95% CI 3093–3937) and €4592 (95% CI 3920–5264), respectively. Dyads and triads associated with cancer, diabetes, chronic fatigue, and genitourinary problems incurred the highest costs. In most cases, the cost associated with multimorbidity was lower or not substantially different from the combined cost of the same conditions observed in separate patients. Conclusion: Prevalent morbidity combinations, rather than high-cost ones, made a greater contribution to total national health expenditure. Our study contributes to the sparse evidence on this topic globally and in Europe, with the aim of improving cost-effective care for patients with diverse needs.


  • Open Access

    An interpretative phenomenological analysis of the lived experience of people with multimorbidity in low- and middle-income countries

    by Phuong Bich Tran, Ayaz Ali, Rubab Ayesha, Jan R Boehnke, Charles Ddungu, Dorothy Lall, Victoria J Pinkney-Atkinson, Josefien van Olmen

    People living with multimorbidity (PLWMM) have multiple needs and require long-term personalised care, which necessitates an integrated people-centred approach to healthcare. However, people-centred care may risk being a buzzword in global health and cannot be achieved unless we consider and prioritise the lived experience of the people themselves. This study captures the lived experiences of PLWMM in low- and middle-income countries (LMICs) by exploring their perspectives, experiences, and aspirations. We analysed 50 semi-structured interview responses from 10 LMICs across three regions—South Asia, Latin America, and Western Africa—using an interpretative phenomenological analysis approach. The bodily, social, and system experiences of illness by respondents were multidirectional and interactive, and largely captured the complexity of living with multimorbidity. Despite expensive treatments, many experienced little improvements in their conditions and felt that healthcare was not tailored to their needs. Disease management involved multiple and fragmented healthcare providers with lack of guidance, resulting in repetitive procedures, loss of time, confusion, and frustration. Financial burden was exacerbated by lost productivity and extreme finance coping strategies, creating a vicious cycle. Against the backdrop of uncertainty and disruption due to illness, many demonstrated an ability to cope with their conditions and navigate the healthcare system. Respondents’ priorities were reflective of their desire to return to a pre-illness way of life—resuming work, caring for family, and maintaining a sense of independence and normalcy despite illness. Respondents had a wide range of needs that required financial, health education, integrated care, and mental health support. In discussion with respondents on outcomes, it appeared that many have complementary views about what is important and relevant, which may differ from the outcomes established by clinicians and researchers. This knowledge needs to complement and be incorporated into existing research and treatment models to ensure healthcare remains focused on the human and our evolving needs.


  • Open Access

    Multimorbidity Healthcare Expenditure in Belgium: A Four-Year Analysis (COMORB study)

    by Phuong Bich Tran, Georgios F Nikolaidis, Emmanuel Abatih, Philippe Bos, Finaba Berete, Vanessa Gorasso, Johan Van der Heyden, Joseph Kazibwe, Ewan M Tomeny, Guido Van Hal, et al.

    Background The complex management of health needs in multimorbid patients, alongside limited cost data, presents challenges in developing cost-effective patient-care pathways. We estimated the costs of managing 171 dyads and 969 triads in Belgium, taking into account the influence of morbidity interactions on costs. Methods We followed a retrospective longitudinal study design, using the linked Belgian Health Interview Survey 2018 and the administrative claim database 2017–2020 hosted by the Intermutualistic Agency. We included people aged 15 and older, who had complete profiles (N = 9,753). Applying a system costing perspective, average annual direct cost per person per dyad/triad was presented in 2022 Euro and comprised mainly of direct medical costs. We developed mixed models to analyze the impact of single chronic conditions, dyads, and triads on healthcare costs, considering two/three-way interactions within dyads/triads, key cost determinants, and clustering at the household level. Results People with multimorbidity constituted nearly half of the study population and their total healthcare cost constituted around three-quarters of the healthcare cost of the study population. The most common dyad, Arthropathies + Dorsopathies, with 14% prevalence rate, accounted for 11% of the total national health expenditure. The most frequent triad, Arthropathies + Dorsopathies + Hypertension, with 5% prevalence rate, contributed 5%. The average annual direct costs per person for dyads and triads were €3,515 (95%CI:3,093 − 3,937) and €4,592 (95%CI:3,920-5,264), respectively. Dyads and triads associated with cancer, diabetes, chronic fatigue, and genitourinary problems incurred the highest costs. In most cases, the cost associated with multimorbidity was lower or not substantially different from the combined cost of the same conditions observed in separate patients. Conclusion Prevalent morbidity combinations, rather than high-cost ones, made a greater contribution to total national health expenditure. Our study contributes to the sparse evidence on this topic globally and in Europe, with the aim of improving cost-effective care for patients with diverse needs.